Diasome to Present at the Solebury Trout Summer 2020 Private Company Showcase
04. August 2020 08:00 ET
|
Diasome Pharmaceuticals, Inc.
CLEVELAND, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Diasome Pharmaceuticals, Inc., a company developing hepatocyte directed vesicle (HDV) technology that can be added to any commercially available insulin...
Diasome to Present at the LifeSci Partners Summer Symposium
28. Juli 2020 08:00 ET
|
Diasome Pharmaceuticals, Inc.
CLEVELAND, July 28, 2020 (GLOBE NEWSWIRE) -- Diasome Pharmaceuticals, Inc., a company developing hepatocyte directed vesicle (HDV) technology that can be added to any commercially available insulin...
Diasome Announces Substantial Reductions in Level 2 Hypoglycemia Events in its Phase 2b OPTI-1 Study of Hepatocyte Directed Vesicle Technology in Type 1 Diabetes
15. Juni 2020 08:00 ET
|
Diasome Pharmaceuticals, Inc.
CLEVELAND, June 15, 2020 (GLOBE NEWSWIRE) -- Diasome Pharmaceuticals, Inc., a company developing hepatocyte directed vesicle (HDV) technology that can be added to any commercially available insulin...
Diasome to Present Data from Phase 2 OPTI-1 Clinical Trial at the 80th Annual American Diabetes Association Virtual Scientific Sessions
04. Juni 2020 08:00 ET
|
Diasome Pharmaceuticals, Inc.
CLEVELAND, June 04, 2020 (GLOBE NEWSWIRE) -- Diasome Pharmaceuticals, Inc., a company developing hepatocyte directed vesicle (HDV) technology that can be added to any commercially available insulin...
Diasome Announces Positive Results from Phase 2 OPTI-1 Study of Hepatocyte Directed Vesicle Technology in Type 1 Diabetes
18. Februar 2020 08:00 ET
|
Diasome Pharmaceuticals, Inc.
CLEVELAND, Feb. 18, 2020 (GLOBE NEWSWIRE) -- Diasome Pharmaceuticals, Inc., a company developing hepatocyte directed vesicle (HDV) technology that can be added to any commercially available insulin...
Diasome to Present Additional Data on Hepatocyte Directed Vesicle Technology in Type 1 Diabetes at the Advanced Technologies & Treatment for Diabetes International Conference
12. Februar 2020 08:00 ET
|
Diasome Pharmaceuticals, Inc.
CLEVELAND, Feb. 12, 2020 (GLOBE NEWSWIRE) -- Diasome Pharmaceuticals, Inc., today announced an upcoming ePoster presentation highlighting additional results from the Phase 2b InSulin Liver Effect-1...
Diasome Appoints Dr. Jeremy Pettus as Chairman of Scientific Advisory Board
10. Dezember 2019 10:00 ET
|
Diasome Pharmaceuticals, Inc.
CLEVELAND, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Diasome Pharmaceuticals today named Dr. Jeremy Pettus the chairman of the company’s scientific advisory board. Dr. Pettus is a board-certified...
Diasome Pharmaceuticals to Participate in the Piper Jaffray 31st Annual Healthcare Conference
26. November 2019 08:00 ET
|
Diasome Pharmaceuticals, Inc.
CLEVELAND, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Diasome Pharmaceuticals, Inc., a company developing hepatocyte directed vesicle (HDV) technology that can be added to any insulin to improve blood...
Diasome Announces Publication of Phase 2b Results in Diabetes Care
24. September 2019 10:51 ET
|
Diasome Pharmaceuticals, Inc.
CLEVELAND, Sept. 24, 2019 (GLOBE NEWSWIRE) -- Diasome Pharmaceuticals today announced the online publication of its InSulin Liver Effect (ISLE-1) Phase 2b study results in respected...
Diasome Announces Completion of Enrollment in Phase 2 OPTI-1 Study of Hepatocyte Directed Vesicle Technology in Type 1 Diabetes
25. Juni 2019 10:04 ET
|
Diasome Pharmaceuticals, Inc.
CLEVELAND, June 25, 2019 (GLOBE NEWSWIRE) -- Diasome Pharmaceuticals, Inc., a company developing hepatocyte directed vesicle (HDV) technology that can be added to any insulin to improve blood...